Targeting HMGB1 in the treatment of sepsis

Bibliography

• Wang H, Zhu S, Zhou R, et al. Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev Mol Med 2008;10:e32
   PubMedGoogle Scholar
• Vincent JL, Opal SM, Marshall JC, et al. Sepsis definitions: time for change. Lancet 2013;381:774-5
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 2008;36:296-327
   PubMed Web of Science ®Google Scholar
• Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10
   PubMed Web of Science ®Google Scholar
• Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005;6:1182-90
   PubMed Web of Science ®Google Scholar
• Liles WC. Immunomodulatory approaches to augment phagocyte-mediated host defense for treatment of infectious diseases. Semin Respir Infect 2001;16:11-17
   PubMedGoogle Scholar
• Ha T, Lu C, Liu L, et al. TLR2 ligands attenuate cardiac dysfunction in polymicrobial sepsis via a phosphoinositide 3-kinase-dependent mechanism. Am J Physiol Heart Circ Physiol 2010;298:H984-91
   PubMed Web of Science ®Google Scholar
• Gao M, Ha T, Zhang X, et al. Toll-like receptor 3 plays a central role in cardiac dysfunction during polymicrobial sepsis. Crit Care Med 2012;40:2390-9
   Google Scholar
• Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732-6
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-8
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511
   PubMed Web of Science ®Google Scholar
• Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunol Today 2000;21:418-20
   PubMedGoogle Scholar
• Chan ED, Riches DW. IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001;280:C441-50
   PubMed Web of Science ®Google Scholar
• Wizemann TM, Gardner CR, Laskin JD, et al. Production of nitric oxide and peroxynitrite in the lung during acute endotoxemia. J Leukoc Biol 1994;56:759-68
   PubMed Web of Science ®Google Scholar
• Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-4
   PubMed Web of Science ®Google Scholar
• Chen G, Li J, Qiang X, et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine:an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 2005;46:623-7
   Google Scholar
• Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003;22:5551-60
   PubMed Web of Science ®Google Scholar
• Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci STKE 2002;2002:E39
   Google Scholar
• Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007;110:1970-81
   PubMed Web of Science ®Google Scholar
• Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012;488:670-4
   PubMed Web of Science ®Google Scholar
• Rendon-Mitchell B, Ochani M, Li J, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003;170:3890-7
   PubMed Web of Science ®Google Scholar
• Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002;3:955-1001
   Google Scholar
• Lamkanfi M, Sarkar A, Vande WL, et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010;185:4385-92
   PubMed Web of Science ®Google Scholar
• Mehta VB, Hart J, Wewers MD. ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J Biol Chem 2001;276:3820-6
   PubMed Web of Science ®Google Scholar
• Griffiths RJ, Stam EJ, Downs JT, Otterness IG. ATP induces the release of IL-1 from LPS-primed cells in vivo. J Immunol 1995;154:2821-8
   PubMedGoogle Scholar
• Perregaux DG, McNiff P, Laliberte R, et al. ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J Immunol 2000;165:4615-23
   PubMed Web of Science ®Google Scholar
• Surprenant A, Rassendren F, Kawashima E, et al. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 1996;272:735-8
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5
   PubMed Web of Science ®Google Scholar
• Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005;201:1135-43
   PubMed Web of Science ®Google Scholar
• Qiu J, Nishimura M, Wang Y, et al. Early release of HMGB-1 from neurons after the onset of brain ischemia. J Cereb Blood Flow Metab 2008;28:927-38
   PubMed Web of Science ®Google Scholar
• Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117:3216-26
   PubMed Web of Science ®Google Scholar
• Cohen MJ, Brohi K, Calfee CS, et al. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care 2009;13:R174
   PubMedGoogle Scholar
• Peltz ED, Moore EE, Eckels PC, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 2009;32:17-22
   PubMed Web of Science ®Google Scholar
• Manganelli V, Signore M, Pacini I, et al. Increased HMGB1 expression and release by mononuclear cells following surgical/anesthesia trauma. Crit Care 2010;14:R197
   Google Scholar
• Zhou RR, Liu HB, Peng JP, et al. High mobility group box chromosomal protein 1 in acute-on-chronic liver failure patients and mice with ConA-induced acute liver injury. Exp Mol Pathol 2012;93:213-19
   Google Scholar
• Takano K, Shinoda M, Tanabe M, et al. Protective effect of high-mobility group box 1 blockade on acute liver failure in rats. Shock 2010;34:573-9
   PubMed Web of Science ®Google Scholar
• Yang R, Zhang S, Cotoia A, et al. High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity. BMC Gastroenterol 2012;12:45
   Google Scholar
• Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013;58:777-87
   PubMed Web of Science ®Google Scholar
• Seo YS, Kwon JH, Yaqoob U, et al. HMGB1 recruits hepatic stellate cells and liver endothelial cells to sites of ethanol induced parenchymal cell injury. Am J Physiol Gastrointest Liver Physiol 2013; Epub ahead of print
   Google Scholar
• Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139-62
   PubMed Web of Science ®Google Scholar
• Zhu S, Li W, Ward MF, et al. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm Allergy Drug Targets 2010;9:60-72
   Google Scholar
• Sursal T, Stearns-Kurosawa DJ, Itagaki K, et al. Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates. Shock 2013;39:55-62
   PubMed Web of Science ®Google Scholar
• Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464:104-7
   PubMed Web of Science ®Google Scholar
• Chen LC, Yeh TM, Wu HN, et al. Dengue virus infection induces passive release of high mobility group box 1 protein by epithelial cells. J Infect 2008;56:143-50
   Google Scholar
• Alleva LM, Budd AC, Clark IA. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 2008;181:1454-9
   PubMed Web of Science ®Google Scholar
• Whilding LM, Archibald KM, Kulbe H, et al. Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther 2013;21(11):2074-86
   PubMed Web of Science ®Google Scholar
• Hofner P, Seprenyi G, Miczak A, et al. High mobility group box 1 protein induction by Mycobacterium bovis BCG. Mediators Inflamm 2007;2007:53805
   PubMed Web of Science ®Google Scholar
• Grover A, Taylor J, Troudt J, et al. Mycobacterial infection induces the secretion of high-mobility group box 1 protein. Cell Microbiol 2008;10:1390-404
   PubMed Web of Science ®Google Scholar
• Wang H, Ward MF, Fan XG, et al. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006;19:3-9
   Google Scholar
• Zhu S, Ashok M, Li J, et al. Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 2009;15:275-82
   Google Scholar
• Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-70
   PubMed Web of Science ®Google Scholar
• Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007;81:59-66
   PubMed Web of Science ®Google Scholar
• Dumitriu IE, Bianchi ME, Bacci M, et al. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007;81:84-91
   PubMed Web of Science ®Google Scholar
• Orlova VV, Choi EY, Xie C, et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007;26:1129-39
   PubMed Web of Science ®Google Scholar
• Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001;152:1197-206
   PubMed Web of Science ®Google Scholar
• Degryse B, de Virgilio M. The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett 2003;553:11-17
   Google Scholar
• Tian J, Avalos AM, Mao SY, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007;8:487-96
   PubMed Web of Science ®Google Scholar
• Yu M, Wang H, Ding A, et al. HMGB1 signals through Toll-like receptor (TLR) 4 and TLR2. Shock 2006;26:174-9
   PubMed Web of Science ®Google Scholar
• Ha T, Xia Y, Liu X, et al. Glucan phosphate attenuates myocardial HMGB1 translocation in severe sepsis through inhibiting NF-kappaB activation. Am J Physiol Heart Circ Physiol 2011;301:H848-55
   PubMed Web of Science ®Google Scholar
• Xiang M, Shi X, Li Y, et al. Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial cells. J Immunol 2011;187:4809-17
   Google Scholar
• Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009;323:1722-5
   PubMed Web of Science ®Google Scholar
• Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005;115:1267-74
   PubMed Web of Science ®Google Scholar
• Salmivirta M, Rauvala H, Elenius K, et al. Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Exp Cell Res 1992;200:444-51
   PubMed Web of Science ®Google Scholar
• Park JS, Svetkauskaite D, He Q, et al. Involvement of TLR 2 and TLR 4 in cellular activation by high mobility group box 1 protein (HMGB1). J Biol Chem 2004;279:7370-7
   PubMed Web of Science ®Google Scholar
• Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24
   PubMed Web of Science ®Google Scholar
• Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61:1-9
   PubMed Web of Science ®Google Scholar
• Pedrazzi M, Patrone M, Passalacqua M, et al. Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol 2007;179:8525-32
   Google Scholar
• Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003;101:2652-60
   PubMed Web of Science ®Google Scholar
• Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003;254:375-85
   PubMed Web of Science ®Google Scholar
• Kazama H, Ricci JE, Herndon JM, et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008;29:21-32
   PubMed Web of Science ®Google Scholar
• Yang H, Lundback P, Ottosson L, et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012;18:250-9
   PubMed Web of Science ®Google Scholar
• Venereau E, Casalgrandi M, Schiraldi M, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012;209:1519-28
   PubMed Web of Science ®Google Scholar
• Tang D, Billiar TR, Lotze MT. A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol Med 2012;18:1360-2
   PubMedGoogle Scholar
• Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock--a review of laboratory models and a proposal. J Surg Res 1980;29:189-201
   PubMed Web of Science ®Google Scholar
• Li W, Zhu S, Zhang Y, et al. Use of animal model of sepsis to evaluate novel herbal therapies. J Vis Exp 2012((62)):3926
   Google Scholar
• Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296-301
   PubMed Web of Science ®Google Scholar
• Wang H, Yang H, Czura CJ, et al. HMGB1 as a Late Mediator of Lethal Systemic Inflammation. Am J Respir Crit Care Med 2001;164:1768-73
   PubMed Web of Science ®Google Scholar
• Abraham E, Arcaroli J, Carmody A, et al. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000;165:2950-4
   PubMed Web of Science ®Google Scholar
• Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006;203:1637-42
   PubMed Web of Science ®Google Scholar
• Suda K, Kitagawa Y, Ozawa S, et al. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006;30:1755-62
   PubMed Web of Science ®Google Scholar
• Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-303
   PubMed Web of Science ®Google Scholar
• Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71
   PubMed Web of Science ®Google Scholar
• Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24
   PubMed Web of Science ®Google Scholar
• Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77
   PubMed Web of Science ®Google Scholar
• Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Iwasaka H, Hasegawa A, et al. High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLP-induced sepsis. Intensive Care Med 2008;34:1812-19
   Google Scholar
• Hagiwara S, Iwasaka H, Matsumoto S, Noguchi T. High dose antithrombin III inhibits HMGB1 and improves endotoxin-induced acute lung injury in rats. Intensive Care Med 2008;34:361-7
   PubMed Web of Science ®Google Scholar
• Li W, Zhu S, Li J, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. PLoS One 2011;6:e16945
   PubMed Web of Science ®Google Scholar
• Hagiwara S, Iwasaka H, Hasegawa A, et al. Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit Care Med 2008;36:2407-13
   PubMed Web of Science ®Google Scholar
• Chorny A, Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 2008;172:1297-307
   Google Scholar
• Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 2008;180:8369-77
   PubMed Web of Science ®Google Scholar
• Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-8
   PubMed Web of Science ®Google Scholar
• Wang H, Czura CJ, Tracey KJ. Lipid unites disparate syndromes of sepsis. Nat Med 2004;10:124-5
   Google Scholar
• Hu YM, Pai MH, Yeh CL, et al. Glutamine administration ameliorates sepsis-induced kidney injury by downregulating the high-mobility group box protein-1-mediated pathway in mice. Am J Physiol Renal Physiol 2012;302:F150-8
   Google Scholar
• Wang H, Li W, Li J, et al. The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 2006;136:360-5
   Google Scholar
• Zhu S, Li W, Li J, et al. It is not just folklore: the aqueous extract of mung bean coat is protective against Sepsis. Evid Based Complement Alternat Med 2012;2012:498467
   Google Scholar
• Jun MS, Kim HS, Kim YM, et al. Ethanol extract of Prunella vulgaris var. lilacina inhibits HMGB1 release by induction of heme oxygenase-1 in LPS-activated RAW 264.7 cells and CLP-induced septic mice. Phytother Res 2012;26:605-12
   PubMed Web of Science ®Google Scholar
• Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004;10:1216-21
   PubMed Web of Science ®Google Scholar
• Li W, Ashok M, Li J, et al. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One 2007;2:e1153
   PubMed Web of Science ®Google Scholar
• Li W, Li J, Ashok M, et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 2007;178:3856-64
   Google Scholar
• Wang W, Zhao F, Fang Y, et al. Glycyrrhizin protects against porcine endotoxemia through modulation of systemic inflammatory response. Crit Care 2013;17:R44
   Google Scholar
• Lee CH, Yoon SJ, Lee SM. Chlorogenic acid attenuates high mobility group box 1 (HMGB1) and enhances host defense mechanisms in murine sepsis. Mol Med 2013;18:1437-48
   Google Scholar
• Lee W, Ku SK, Kim TH, Bae JS. Emodin-6-O-beta-D-glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo. Food Chem Toxicol 2013;52:97-104
   PubMed Web of Science ®Google Scholar
• Yang EJ, Ku SK, Lee W, et al. Barrier protective effects of rosmarinic acid on HMGB1-induced inflammatory responses in vitro and in vivo. J Cell Physiol 2013;228:975-82
   PubMed Web of Science ®Google Scholar
• Kim TH, Ku SK, Bae JS. Anti-inflammatory activities of isorhamnetin-3-O-galactoside against HMGB1-induced inflammatory responses in both HUVECs and CLP-induced septic mice. J Cell Biochem 2013;114:336-45
   PubMed Web of Science ®Google Scholar
• Kim TH, Ku SK, Bae JS. Persicarin is anti-inflammatory mediator against HMGB1-induced inflammatory responses in HUVECs and in CLP-induced sepsis mice. J Cell Physiol 2013;228:696-703
   Google Scholar
• Jiang WL, Yong X, Zhang SP, et al. Forsythoside B protects against experimental sepsis by modulating inflammatory factors. Phytother Res 2012;26:981-7
   PubMed Web of Science ®Google Scholar
• Yang M, Cao L, Xie M, et al. Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem Pharmacol 2013;86(3):410-18
   PubMed Web of Science ®Google Scholar
• Seo ES, Oh BK, Pak JH, et al. Acteoside improves survival in cecal ligation and puncture-induced septic mice via blocking of high mobility group box 1 release. Mol Cells 2013;35:348-54
   Google Scholar
• Li W, Zhu S, Li J, et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem Pharmacol 2011;81:1152-63
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li W, Zhu S, et al. Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake. Biochem Pharmacol 2012;84:1492-500
   Google Scholar
• Lu B, Wang H, Andersson U, et al. Regulation of HMGB1 release by inflammasomes. Protein Cell 2013;4:163-7
   PubMed Web of Science ®Google Scholar
• Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J Nutr 1998;128:2334-40
   PubMed Web of Science ®Google Scholar
• Ichikawa D, Matsui A, Imai M, et al. Effect of various catechins on the IL-12p40 production by murine peritoneal macrophages and a macrophage cell line, J774.1. Biol Pharm Bull 2004;27:1353-8
   PubMed Web of Science ®Google Scholar
• Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006;177:1967-74
   PubMed Web of Science ®Google Scholar
• Heuer JG, Sharma GR, Gerlitz B, et al. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit Care Med 2004;32:1570-8
   PubMed Web of Science ®Google Scholar
• Li W, Li J, Sama AE, et al. Carbenoxolone Blocks Endotoxin-Induced Protein Kinase R (PKR) Activation and High Mobility Group Box 1 (HMGB1) Release. Mol Med 2013;19:203-11
   Google Scholar
• Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429-36
   PubMed Web of Science ®Google Scholar
• Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000;356:961-7
   PubMed Web of Science ®Google Scholar
• Opal SM, Laterre PF, Francois B, et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013;309:1154-62
   PubMed Web of Science ®Google Scholar
• Hagar JA, Powell DA, Aachoui Y, et al. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 2013;341:1250-3
   PubMed Web of Science ®Google Scholar
• Kayagaki N, Wong MT, Stowe IB, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013;341:1246-9
   PubMed Web of Science ®Google Scholar
• Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71
   PubMed Web of Science ®Google Scholar
• Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934-41
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yao YM, Huang LF, et al. The potential effect and mechanism of high-mobility group box 1 protein on regulatory T cell-mediated immunosuppression. J Interferon Cytokine Res 2011;31:249-57
   Google Scholar
• Wild CA, Bergmann C, Fritz G, et al. HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol 2012;24:485-94
   Google Scholar
• Aneja RK, Tsung A, Sjodin H, et al. Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J Leukoc Biol 2008;84:1326-34
   PubMed Web of Science ®Google Scholar
• Robert SM, Sjodin H, Fink MP, et al. Preconditioning with high mobility group box 1 (HMGB1) induces lipoteichoic acid (LTA) tolerance. J Immunother 2010;33:663-71
   Google Scholar
• Entezari M, Weiss DJ, Sitapara R, et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis. Mol Med 2012;18:477-85
   PubMed Web of Science ®Google Scholar
• Patel VS, Sitapara RA, Gore A, et al. High Mobility Group Box-1 mediates hyperoxia-induced impairment of Pseudomonas aeruginosa clearance and inflammatory lung injury in mice. Am J Respir Cell Mol Biol 2013;48:280-7
   PubMed Web of Science ®Google Scholar
• Liu G, Wang J, Park YJ, et al. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol 2008;181:4240-6
   PubMed Web of Science ®Google Scholar
• Ji XY, Tan BK, Zhu YZ. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 2000;21:1089-94
   PubMed Web of Science ®Google Scholar